{
    "clinical_study": {
        "@rank": "23647", 
        "brief_summary": {
            "textblock": "The purpose of this study is to find out if the two different formulations of exemestane\n      (Aromasin), oral and injectable, are equivalent in terms of pharmacodynamics and\n      pharmacokinetics, i.e., if ultimately both formulations have the same efficacy in\n      postmenopausal women with metastatic breast cancer who have failed previous antiestrogens\n      therapy and are equally safe."
        }, 
        "brief_title": "Open Label, Multicenter, Randomized, Controlled Study of IM or Oral Exemestane (Aromasin) in Postmenopausal Women", 
        "completion_date": {
            "#text": "December 2006", 
            "@type": "Actual"
        }, 
        "condition": "Breast Neoplasms", 
        "condition_browse": {
            "mesh_term": [
                "Breast Neoplasms", 
                "Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  other diagnosed with breast cancer\n\n          -  estrogen receptor positivity\n\n          -  Postmenopausal status\n\n          -  advanced disease\n\n          -  progression to previous tamoxifen therapy\n\n        Exclusion Criteria:\n\n          -  more than 1 chemotherapy and / or more than 1 hormonotherapy for advanced disease\n\n          -  previous hormonotherapy other than Tamoxifen"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "100", 
        "firstreceived_date": "June 18, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00040014", 
            "org_study_id": "971-ONC-0401-003"
        }, 
        "intervention": {
            "intervention_name": "exemestane", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Exemestane"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "February 14, 2012", 
        "link": {
            "description": "To obtain contact information for a study center near you, click here.", 
            "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=971-ONC-0401-003&StudyName=Open+Label%2C+Multicenter%2C+Randomized%2C+Controlled+Study+of+IM+or+Oral+Exemestane+%28Aromasin%29+in+Postmenopausal+Women"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Leicester", 
                    "country": "United Kingdom"
                }, 
                "name": "Pfizer Investigational Site"
            }
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "official_title": "Open Label, Multicenter, Randomized, Controlled Study of IM or Oral Exemestane (Aromasin) in Postmenopausal Women With Advanced Breast Cancer Having Progressed on Tamoxifen.", 
        "overall_official": {
            "affiliation": "Pfizer", 
            "last_name": "Pfizer CT.gov Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2006", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "To determine the pharmacodynamic equivalence at steady state of the IM formulation of exemestane with the oral formulation in terms of plasma estrone sulphate inhibitory effect in postmenopausal women with advanced breast cancer."
        }, 
        "removed_countries": {
            "country": "United States"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00040014"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "to characterize the pharmacodynamic profile of the two formulations in terms of estrogens, androgens, and sec hormone binding globulin"
            }, 
            {
                "measure": "to characterize the pharmacokinetics of exemestane and 17 hydroexemestane after administration of the two formulations"
            }, 
            {
                "measure": "to evaluate the relationships between pharmacokinetics and pharmacodynamics after intramuscular and oral administration of exemestane"
            }, 
            {
                "measure": "to evaluate the efficacy (as tumor response)"
            }, 
            {
                "measure": "to evaluate the incidence and severity of systemic toxicities and of the local tolerability of the injectable formulation"
            }, 
            {
                "measure": "to evaluate the effect on serum bone turnover markers"
            }
        ], 
        "source": "Pfizer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2002", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2012"
    }, 
    "geocoordinates": {
        "Pfizer Investigational Site": "52.637 -1.14"
    }
}